DCAG方案治疗难治复发淋系肿瘤6例疗效分析  

Effect of DCAG regimen in the treatment of refractory recurrent lymphoid neoplasm in 6 cases

作　　者：寇丹婷 冯延丽 何雨晨 葛繁梅[1] KOU Danting;FENG Yanli;HE Yuchen;GE Fanmei(Department of Hematology,Yan'an University Affiliated Hospital,Yan'an 716000,Shaanxi Province,China)

机构地区：[1]延安大学附属医院血液科,陕西延安716000

出　　处：《数理医药学杂志》2024年第2期149-153,共5页Journal of Mathematical Medicine

摘　　要：目的探讨地西他滨+阿糖胞苷+阿克拉霉素+粒细胞集落刺激因子(DCAG)方案治疗难治复发淋系肿瘤的有效性及安全性。方法回顾性分析延安大学附属医院血液科2020年1月至2021年12月收治的6例难治复发淋系肿瘤患者的临床资料,评估其疗效。结果6例患者中,急性B淋巴细胞白血病(B-acute lymphoblastic leukemia,B-ALL)4例、弥漫大B细胞淋巴瘤1例、外周T细胞淋巴瘤1例。患者在1疗程诱导化疗方案结束后,总反应率为100%,不良反应以血液科患者化疗后均会出现的三系细胞减少及相应并发症为主,通过对症治疗后均能得到纠正。结论DCAG方案治疗难治复发淋系肿瘤的有效性及安全性尚可,但病例数较少,需进一步收集更多临床病例。Objective To investigate the efficacy and safety of decitabine+cytarabine+acclarithromycin+granulocyte colony stimulating factor(DCAG)regimen in the treatment of refractory recurrent lymphoid neoplasm.Methods A retrospective analysis was conducted on 6 patients with refractory relapsed lymphoid neoplasm in the department of hematology,Yan'an University Affiliated Hospital from January 2020 to December 2021,and to evaluate the curative effect.Results Among all the cases,4 cases were with B-acute lymphoblastic leukemia(B-ALL),1 case was with diffuse large B-cell lymphoma and 1 case was with peripheral T-cell lymphoma.After 1 course of induction chemotherapy,the overall response rate of the patients was 100%,and the adverse reactions were mainly the erythrocyte leukocyte and thrombocytopenia and corresponding complications that all patients in hematology department would appear after chemotherapy,which could be corrected by symptomatic treatment.Conclusion DCAG regimen is effective and safe in the treatment of refractory recurrent lymphoid neoplasm,but is small,and more clinical cases need to be collected.

关 键 词：DCAG方案 淋系肿瘤 难治复发 

分 类 号：R733[医药卫生—肿瘤]